Nature Cancer

Nature Cancer

自然癌症

  • 1区 中科院分区
  • Q1 JCR分区

期刊简介

《Nature Cancer》是由Springer Nature出版社创办的英文国际期刊(ISSN: 2662-1347,E-ISSN: 2662-1347),该期刊长期致力于肿瘤学领域的创新研究,主要研究方向为Medicine-Oncology。作为SCI、SCIE收录期刊(JCR分区 Q1,中科院 1区),本刊采用OA未开放获取模式(OA占比%),以发表肿瘤学领域等方向的原创性研究为核心(研究类文章占比88.03%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在117篇,确保学术质量与前沿性。成果覆盖Web of ScienceWeb of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Nature Cancer该刊近年未被列入国际预警名单,年发文量约117篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCI、SCIE 期刊收录
  • 117 发文量

中科院分区

《新锐期刊分区表》(2026年3月发布)

Top期刊 综述期刊 大类学科 小类学科
医学
1区
ONCOLOGY 肿瘤学
1区

期刊分区表(2025年3月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
1区
ONCOLOGY 肿瘤学
1区

期刊分区表(2023年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
1区
ONCOLOGY 肿瘤学
1区

期刊分区表(2022年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
1区
ONCOLOGY 肿瘤学
1区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 12 / 333

96.5

学科:ONCOLOGY SCIE Q1 10 / 333

97.15

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 11 / 322

96.7

学科:ONCOLOGY SCIE Q1 10 / 322

97.05

CiteScore(2026年6月最新版)

CiteScore SJR SNIP CiteScore 排名
CiteScore:38.5 SJR:12.443 SNIP:4.601
学科类别 分区 排名 百分位
大类:Medicine 小类:Oncology Q1 10 / 428

97%

大类:Medicine 小类:Cancer Research Q1 8 / 233

96%

期刊发文

  • Multi-omic characterization of nasopharyngeal carcinoma delineates the subtype-specific landscape of response to induction chemotherap

    Author: Li, Yingqin; Wang, Dongxue; Ou, Chunxian; Liu, Zaoqu; Shao, Xianfeng; Zhao, Yuheng; Zhang, Xinxin; Shen, Jiaxi; He, Qingmei; Liu, Xu; Zhang, Yuan; Liang, Xiaoyu; Li, Yaoyi; Huang, Huimin; Xie, Linhai; Wang, Gaoyuan; Liang, Yelin; Li, Kaixuan; Yan, Meng; Yang, Qianying; Tang, Linglong; Chen, Lei; Zhao, Yin; Xu, Sha; Sun, Ying; Yue, Jia-Xing; Liu, Na; Sun, Aihua; Ma, Jun; He, Fuchu

    Journal: NATURE CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1038/s43018-026-01149-8

  • TMEM87A suppresses ferroptosis and increases cancer immunotherapy resistance by maintaining the Golgi apparatus pH homeostasi

    Author: Li, Jing; Zhou, Yuhan; Li, Xiong; Yin, Songlin; Gao, Yuan; Shang, Haotian; Lai, Yongfeng; Yang, Liguo; Xue, Ying; Li, Xiaoxiao; Li, Yan; Chang, Zhenzhen; Chen, Jing; Cheng, Xiang; Zhang, Xiaoyan; Chu, Qian; Lu, Fujia; Wang, Weimin

    Journal: NATURE CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1038/s43018-026-01156-9

  • DeepFAN, a transformer-based model for human-artificial intelligence collaborative assessment of incidental pulmonary nodules in CT scans: a multireader, multicase tria

    Author: Zhu, Zhenchen; Hu, Ge; Tan, Weixiong; Gao, Kai; Sun, Chao; Zhou, Zhen; Xu, Kepei; Han, Wei; Shang, Meixia; Qiu, Xiaoming; Tan, Yiqing; Wang, Jinhua; Ying, Zhoumeng; Peng, Li; Song, Wei; Song, Lan; Jin, Zhengyu; Hong, Nan; Yu, Yizhou

    Journal: NATURE CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1038/s43018-026-01147-w

  • Eythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 tria

    Author: Nie, Xiaoqian; Liu, Yuehua; Yao, Xingyun; Zhang, Qi; Huang, Yanjie; Mattursun, Kurban; Feng, Yuxiong; Liang, Tingbo; Yang, Liu; Gao, Xiaofei

    Journal: NATURE CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1038/s43018-026-01125-2

  • Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 tria

    Author: Gao, Yang; Li, Jie; Zhang, Hangyu; Zhang, Yingzi; Qian, Siyuan; Zhu, Xudong; Hong, Libing; Xie, Li; Fu, Qihan; Bao, Xuanwen; Tong, Zhou; Li, Yunyan; Li, Bin; Wang, Linling; Shen, Junjie; Zhang, Qianzhen; He, Xiao; Zheng, Yi; Yao, Chao; Liu, Lulu; Zhao, Peng; Campos, Pedro Villarejo; Yang, Zhi; Qian, Cheng; Fang, Weijia

    Journal: NATURE CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1038/s43018-026-01124-3

  • CRTAM inhibition mitigates toxicity of immune checkpoint inhibitors without antitumor efficacy trade-of

    Author: Ma, Si-Cong; Rong, Zi-Xuan; Xu, Zi-Peng; Zhang, Yan-Pei; Zhuang, Kui-Mao; Sun, Hao; Cao, Chuan-Hui; Wu, Ze-Nan; Zhang, Hai-Peng; Zuo, Qiang; Lin, Jia-Run; Cheng, Jia-Xin; Qu, Hua-Ting; Han, Duan-Duan; Wei, Wei; Liu, Ke; Cai, Xiao-Ting; Guo, Ze-Qin; Bai, Xue; Liu, Li; Wu, De-Hua; Dong, Zhong-Yi

    Journal: NATURE CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1038/s43018-026-01135-0

  • Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxteca

    Author: Xu, Jing; Liu, Jing; Liu, Yang; Huang, Ting; Yi, Yong; Bai, Ruixiao; Zheng, Haorui; Chen, Xiaoli; Gao, Jiexin; Lian, Xin; Guo, Rongtian; Xu, Chuan; Li, Qintong; Zhang, Yujun; Cao, Yang; Mi, Peng; Xiao, Zhi-Xiong Jim; Niu, Mengmeng

    Journal: NATURE CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1038/s43018-025-01112-z

  • METTL3-based epitranscriptomic editing screening identifies functional m6A sites in cancer

    Author: Xu, Xin; Wang, Yujuan; Zhu, Helen; Lam, Magnus; Luo, Wenqin; Teng, Mona; Liu, Yin; Guo, Wang Yuan; Aastha, Aastha; Xu, Xi; Chen, Sujun; Ci, Xinpei; Wang, Shiyan; Zeng, Yong; Zhu, Guanghui; Kislinger, Thomas; Lupien, Mathieu; Tsao, Ming-Sound; He, Housheng Hansen

    Journal: NATURE CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1038/s43018-026-01117-2